HCW Biologics Company Insiders
HCWB Stock | USD 4.50 0.21 4.46% |
HCW Biologics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding HCW Biologics suggests that all insiders are extremely bullish. HCW Biologics employs about 36 people. The company is managed by 5 executives with a total tenure of roughly 84 years, averaging almost 16.0 years of service per executive, having 7.2 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
2025-05-08 | Rebecca Byam | Acquired 8462 @ 26 | View |
Monitoring HCW Biologics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. HCW Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (277.2596) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 4.66, whereas Return On Tangible Assets are forecasted to decline to (1.04). At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Current Assets Total are forecasted to decline to about 14.2 M.The current year's Common Stock Shares Outstanding is expected to grow to about 40.3 M, whereas Net Loss is forecasted to decline to (14.1 M).
HCW Biologics Workforce Comparison
HCW Biologics is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 517. HCW Biologics holds roughly 36.0 in number of employees claiming about 7% of equities under Health Care industry.
HCW Biologics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific HCW Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on HCW Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, HCW Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-12-01 | 1.0 | 4 | 4 | 83,750 | 83,750 |
2023-06-01 | 22.0 | 22 | 1 | 255,550 | 5,356 |
2022-12-01 | 1.0 | 1 | 1 | 33,750 | 33,750 |
2022-03-01 | 1.0 | 2 | 2 | 1,715 | 1,715 |
2021-12-01 | 1.5 | 6 | 4 | 145,396 | 31,285 |
2021-09-01 | 1.2917 | 31 | 24 | 15,982,536 | 31,672,357 |
HCW Biologics Notable Stakeholders
A HCW Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as HCW Biologics often face trade-offs trying to please all of them. HCW Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting HCW Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Raquel MS | Director Resources | Profile | |
Hing Wong | CEO, Founder | Profile | |
Lee Flowers | Senior Development | Profile | |
Peter Rhode | Chief Operations | Profile | |
Nicole Esq | Vice Affairs | Profile |
About HCW Biologics Management Performance
The success or failure of an entity such as HCW Biologics often depends on how effective the management is. HCW Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HCW management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HCW management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.99) | (1.04) | |
Return On Capital Employed | (48.51) | (46.09) | |
Return On Assets | (0.99) | (1.04) | |
Return On Equity | 4.43 | 4.66 |
Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.
HCW Biologics Workforce Analysis
Traditionally, organizations such as HCW Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare HCW Biologics within its industry.HCW Biologics Manpower Efficiency
Return on HCW Biologics Manpower
Revenue Per Employee | 71.3K | |
Revenue Per Executive | 513.4K | |
Net Loss Per Employee | 834K | |
Net Loss Per Executive | 6M |
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |